UCB and Novartis have announced a new licensing agreement to market cardiovascular and diabetes products in Germany.
Under the agreement UCB has extended commercial rights for the German market to the cardiovascular medication Provas (valsartan) beyond 2011 and has licensed commercial rights for two line extensions for Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT).
Dafiro HCT in particular is seen as a major breakthrough drug for the treatment of hypertension as it is the first drug approved for the condition in 25 years.
UCB vice-president Willy Cnops said that the company is extending its cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date.
“With this agreement we are building on our strengths in Germany and our excellent position in the internal medicine segment,” said Cnops.
In addition, UCB will also co-commercialise two new oral anti-diabetics Jalra and Icandra (vildagliptin and vildagliptin + metformin).